Explore

Trendline Trendline
Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting

Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting

Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting
Trendline Trendline
Roche's Oral BTK Inhibitor Shows Promise in Multiple Sclerosis Trials

Roche's Oral BTK Inhibitor Shows Promise in Multiple Sclerosis Trials

Roche's Oral BTK Inhibitor Shows Promise in Multiple Sclerosis Trials
Trendline Trendline
Genentech's Fenebrutinib Shows Promising Results in Reducing Relapses in Multiple Sclerosis

Genentech's Fenebrutinib Shows Promising Results in Reducing Relapses in Multiple Sclerosis

Genentech's Fenebrutinib Shows Promising Results in Reducing Relapses in Multiple Sclerosis
Trendline Trendline
Ionis Pharmaceuticals' Antisense Drug Shows Promise for Rare Neurological Disease

Ionis Pharmaceuticals' Antisense Drug Shows Promise for Rare Neurological Disease

Ionis Pharmaceuticals' Antisense Drug Shows Promise for Rare Neurological Disease
Trendline Trendline
FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment
Trendline Trendline
Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026

Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026
Trendline Trendline
Ono Pharma to Present New Cancer Treatment Data at ASCO 2026 Meeting in Chicago

Ono Pharma to Present New Cancer Treatment Data at ASCO 2026 Meeting in Chicago

Ono Pharma to Present New Cancer Treatment Data at ASCO 2026 Meeting in Chicago
Trendline Trendline
PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Trendline Trendline
Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment
Trendline Trendline
Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results

Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results

Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results
Trendline Trendline
Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment

Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment

Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer